Capacity Worries Fade for Biomanufacturing

Published on: 
Pharmaceutical Technology, Pharmaceutical Technology-07-02-2003, Volume 27, Issue 7

The DSM investment puts biomanufacturing capacity in the spotlight. Contract biomanufacturers are adding new capacity and sponsors are marketing their excess capacity.

Related Content:

OutsourcingOutsourcing OutlookPharmaceutical Technology-07-02-2003
Samsung Biologics Expands Strategic Manufacturing Agreement with Bristol Myers Squibb
CN Bio and LifeNet Health LifeSciences Partner to Supply Pre-Validated Cells
Illumina Establishes New Center in India to Expand Genomics Capabilities